Drug Trial Radar · NCT07924111
A Randomized, Controlled, Double-Blind, Multicenter Phase III Clinical Trial to Evaluate the Efficacy and Safety of Enlonstobart, With or Without SYS6010 as Adjuvant Therapy, in Participants With Pathologically Residual Esophageal Squamous Cell Carcinoma Following Complete Surgical Resection
Last checked: Nov 19, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
585
Planned (sponsor's estimate)
Start
Dec 30, 2026
Primary completion
Dec 30, 2029
Study completion Dec 30, 2030
Sponsor
- Lead sponsor
- CSPC Megalith Biopharmaceutical Co.,Ltd.Industry
- Sponsor type
- Industry
- First posted
- Nov 9, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomized, controlled, double-blind, multicenter phase iii clinical trial to evaluate the efficacy and safety of enlonstobart, with or without SYS6010 as adjuvant therapy, in participants with pathologically residual esophageal squamous cell carcinoma following complete surgical resection.
Conditions
- Esophageal Squamous Cell Carcinoma
Interventions
SYS6010Drug
SYS6010 is an antibody conjugate drug (ADC), composed of one anti-EGFR monoclonal antibody coupled to one JS1 via an enzyme specific linker.
SG001Drug
SG001 is a recombinant, fully human, anti-PD-1 monoclonal antibody.
SG001 placebo-mimickingDrug
SG001 placebo-mimicking is a placebo mimicking of SG001
SYS6010 placebo-mimickingDrug
SYS6010 placebo-mimicking is a placebo mimicking of SYS6010
Primary outcomes
What the sponsor says the trial is designed to measure.
- DFSTime frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 60 months
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.